Aadi (United States)

Recent papers from Aadi (United States)

1. Tolerance and prediction intervals: The Bayesian wayJournal of Biopharmaceutical Statistics · 2026
2. Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 TrialClinical Cancer Research · 2025
3. Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin LymphomaClinical Cancer Research · 2025
4. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaBlood Cancer Discovery · 2024
5. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazardPharmaceutical Statistics · 2023
6. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Blood Cancer Discovery · 2023
7. Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11Clinical Cancer Research · 2023
8. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaClinical Cancer Research · 2023
9. Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal CancerMolecular Cancer Therapeutics · 2018